TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03426423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral smoking cessation intervention
Description: The intervention consists in a behavioral smoking cessation intervention combined with pharmacotherapy. The intervention is tailored it to specificities of participants based on findings from the previous phase of our study (DISCGO-MIX, Swissethics ID PB_2016-01459).~Counseling will cover topics such as assessing ambivalence and enhancing motivation with motivational interviewing methods, identifying barriers to quit, coping with cravings and intensive relapse prevention strategies. Participants will be advised to use over the counter nicotine replacement bi-therapy (NTR). A 2-week starting kit, consisting of nicotine transdermal patch and a short acting NRT (lozenge, gums, inhaler or mouth spray) will be provided to participants for free, if they wish to take NRT.~The behavioral intervention will last 30-45 minutes, and will be conducted by a research nurse using an interview guide.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants assigned to the control group will receive a less intensive and non-tailored intervention for smoking cessation.~For this arm the structured 3 steps AAR approach will be used:~Ask for smoking status. Advise to quit in a clear manner. Refer to external help: participants will receive a booklet with information on smoking cessation (non specific to diabetes and gender) and links to support facilities (national quitline, smoking cessation clinic, websites, self-help).~This unique intervention of 5-10 minutes will be performed by the research nurse.
Study: NCT00982007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate Tablets
Description: 325 mg Ferrous Sulfate tablets taken orally three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Iron (standard of care)
Description: IV standard of care (other IV iron) per the Investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
Study: NCT02237404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine System
Description: Telemedicine System is used in remote monitoring group
Study: NCT02511678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: The application of repeated freeze and thaw cycles to the identified tissues.
Study: NCT03253939

Intervention type: PROCEDURE
Intervention: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
Description: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure

Intervention type: PROCEDURE
Intervention: Cytoreductive surgery alone
Description: Exclusively Cytoreductive surgery approach
Study: NCT00640055

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coordinator
Description: Coordinator (non-physician) assigned cause of death

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physician-assigned cause of death
Description: Physician (gold standard) cause of death
Study: NCT03065023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4621
Description: IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4621
Description: IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
Study: NCT02827240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral HIV Self-Testing
Description: The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral HIV Self-Testing
Description: The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
Study: NCT01380639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration training
Description: performing squats for 3x3 minutes while using vibration platform three times a week
Study: NCT02357823

Intervention type: OTHER
Intervention: Evaluation of immunological response
Description: Study of short and long term immunological response after different schedule of PCV13 or PPV23

Intervention type: OTHER
Intervention: Evaluation of immunological response
Description: Study of short and long term immunological response after different schedule of PCV13 or PPV23

Intervention type: OTHER
Intervention: Evaluation of immunological response
Description: Study of short and long term immunological response after different schedule of PCV13 or PPV23

Intervention type: OTHER
Intervention: Evaluation of immunological response
Description: Study of short and long term immunological response after different schedule of PCV13 or PPV23

Intervention type: OTHER
Intervention: Evaluation of immunological response
Description: Study of short and long term immunological response after different schedule of PCV13 or PPV23

Intervention type: OTHER
Intervention: Nasopharyngeal swabs analysis
Description: Evaluation of pneumococcal nasopharyngeal colonization

Intervention type: OTHER
Intervention: Nasopharyngeal swabs analysis
Description: Evaluation of pneumococcal nasopharyngeal colonization

Intervention type: OTHER
Intervention: Nasopharyngeal swabs analysis
Description: Evaluation of pneumococcal nasopharyngeal colonization

Intervention type: OTHER
Intervention: Nasopharyngeal swabs analysis
Description: Evaluation of pneumococcal nasopharyngeal colonization

Intervention type: OTHER
Intervention: Nasopharyngeal swabs analysis
Description: Evaluation of pneumococcal nasopharyngeal colonization
Study: NCT00680823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
Study: NCT03511404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy rehabilitation
Description: All subjects will receive a course of conventional physiotherapy that incorporating components of pain relief and functional restoration with the use of electrotherapy and exercise therapy for twelve sessions twice weekly in six weeks guided by a registered physiotherapist in Hong Kong.
Study: NCT01864772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbo, 5FU, Cetuximab
Description: 6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity
Study: NCT01353079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Short Ragweed Pollen Allergenic Extract
Description: Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Glycero-COCAs sublingual
Study: NCT02849301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arabin cervical pessary
Study: NCT00522912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trichiasis surgery
Description: Posterior lamella tarsal rotation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epilation
Description: Epilation of lashes by another well sighted person using quality epilating forceps
Study: NCT02877212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.
Study: NCT01548924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib + Paclitaxel
Description: * Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~* Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days.
Study: NCT01655927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Saline
Study: NCT02493894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: PEG solution (80gr/1Litr) each 8 hours for 24 hours

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: placebo each 8 hours for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: cefazolin 1gram, every 6hours for 2 days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cefazolin
Description: cefazolin 1gram, every 6hours for 2 days
Study: NCT04603586

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT: in 5-6 fractions with CyberKnife

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT: in 5-6 fractions with CyberKnife

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
Study: NCT04354090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: Subcutaneous injection
Study: NCT03211247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part A Viaskin Peanut 250 mcg
Description: Viaskin Peanut 250 mcg, once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part A Viaskin Peanut 100 mcg
Description: Viaskin Peanut 100 mcg, once daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Part A Placebo
Description: Placebo patch, once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part B Viaskin Peanut 250 mcg
Description: Viaskin Peanut 250 mcg, once daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Part B Placebo
Description: Placebo patch, once daily
Study: NCT03876314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Condition
Description: Subjects will attend virtual group exercise sessions 3x/week for 1 year. Each subject will be encouraged to walk at a moderate intensity (target heart rate (HR)= 40-59% HR reserve) dependent on resting HR and age. Subjects will perform aerobic exercise on their own and resistance exercises will be completed in virtual exercise sessions with an instructor 1 hour/day for 3 days/week for 1 year. At the exercise sessions, these participants will be asked to record measures of the exercises completed and may be asked to provide measures of heart rate (assessed by palpation for 20-seconds) and rate of perceived exertion (RPE). They will be asked to submit exercise logs providing this information. Data from exercise logs and exercise specialist records will be reviewed for evidence of progression, consistent attainment of moderate intensity, and with respect to the prescribed duration of the aerobic and strength training components.
Study: NCT03701763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast (CC-10004)
Description: Apremilast (CC-10004)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast (CC-10004)
Description: Apremilast (CC-10004)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04307277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care + chemotherapy
Description: Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Surgical excision with external radiotherapy (if applicable)
Study: NCT04246086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (IV)
Description: Participants will receive IV mosunetuzumab as defined by the study protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (IV)
Description: Participants will receive IV mosunetuzumab as defined by the study protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide as defined by the study protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide as defined by the study protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide as defined by the study protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide as defined by the study protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (SC)
Description: Participants will receive SC mosunetuzumab as defined by the study protocol
Study: NCT04663308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volixibat
Description: Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volixibat
Description: Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volixibat
Description: Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules matched to study drug minus active substance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules matched to study drug minus active substance
Study: NCT03073226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Elite
Description: New generation Olympus endoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Elite
Description: New generation Olympus endoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Spectrum
Description: Current generation Olympus endoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Spectrum
Description: Current generation Olympus endoscope
Study: NCT02947477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EmoTrak
Description: Ecological Momentary Assessment of Emotion through Iphone App
Study: NCT00782288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: digitoxin
Description: 0.05mg tabs, once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: digitoxin
Description: 0.1mg pills, once daily for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pill taken once daily for 28 days
Study: NCT02764450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astralis 10 HPM
Description: The cavity to be filled is in quadrant I or III

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astralis 10 RM
Description: The cavity to be filled is in quadrant II or IV
Study: NCT04339114

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Breakfast: control meal
Description: The breakfast meal includes a Taiwanese style pancake plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast: Cinnamon meal
Description: The breakfast meal includes a Taiwanese style pancake seasoned with grounded cinnamon plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast: Italian herbs meal
Description: The breakfast meal includes a Taiwanese style pancake seasoned with Italian herbs plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast: pumpkin spice
Description: The breakfast meal includes a Taiwanese style pancake seasoned with pumpkin spices plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
Study: NCT00174265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: 5-10 mg sublingually twice daily for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 5-20 mg by mouth once daily for 26 weeks
Study: NCT01119326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Transfer
Description: one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Fat Transfer
Description: one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
Study: NCT02342756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeting transpulmonary pressure to avoid VILI
Description: Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeting transpulmonary pressure to avoid VILI
Description: Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
Study: NCT03359213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion (lyophilized powder), 1.0 mg/kg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion (lyophilized powder), 2.0 mg/kg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion (lyophilized powder), 4.0 mg/kg/week
Study: NCT02204566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI Capsule
Description: Imaging of the esophagus using the OFDI Capsule and system
Study: NCT00047320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: craniospinal irradiation
Study: NCT01875536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: conventional physical therapy
Description: The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
Study: NCT00064389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol tartrate HFA MDI
Description: levalbuterol MDI 90 mcg QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic albuterol
Description: racemic albuterol HFA MDI 180 mcg QID
Study: NCT02429297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HITCM-only
Description: HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HITCM-only
Description: HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HITCM+CP
Description: HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.